Jay Tibbitts has 25+ years of experience in building and leading industry-leading functional and project teams in biotech and pharma. He has a strong scientific record in translational pharmacology, drug development, and PKPD, as well as extensive experience with antibody-drug conjugates and biotherapeutics from Discovery to Development, including related Regulatory filings. Jay most recently served as the VP of Nonclinical Development at Surrozen, a biotech company pioneering a new class of targeted regenerative antibodies to repair tissues and organs damaged by disease. Jay has also led Nonclinical PK-PD teams at AbbVie, UCB, and Genentech. He specializes in regenerative medicine, oncology, antimicrobials, immunology, and neuroscience. Jay has a PhD in Biopharmaceutical Sciences from UCSF.